FibroGen에 대한 매도 수량은 투자자에게 FibroGen의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

FibroGen (NASDAQ:FGEN) 주식, 공매도 수량 보고

FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Biotech

News

Contracts

After-Hours Center

Movers

FGEN

REGN

피브로젠(NASDAQ:FGEN)의 주가는 회사가 미국 식품의약국(FDA)이 FG-3165에 대한 임상시험용 신약(IND)을 승인했다고 발표한 후 월요일 시간외 세션에서 급등했다. 이 회사는 또한 리제네론(NASDAQ:REGN)과 새로운 임상시험 공급 계약을 발표했다. 사건의 전말 (What Happened): 피브로젠은 월요일 시장 마감 후 FDA가 FG-3165의 IND를 승인하여 회사가 1상 임상 시험을 시작할 수 있게 되었다고 말했다.

피브로젠: 미 FDA의 임상시험용 신약 승인 발표 후 주가 급등

FibroGen Inc

WIIM

FibreGen shares are trading higher. The stock may be moving on continued strength following a Q3 earnings beat reported on Tuesday.

Guidance

FibroGen Reiterates Full Year Net Product Revenue Guidance Of $135M-$150M

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.38) by 55.26 percent. The company reported quarterly sales of $46.333 million which beat the analyst consensus estimate of $34.763 million by 33.28 percent. This is a 15.45 percent increase over sales of $40.134 million the same period last year.

Earnings

Earnings Beats

FibroGen Q3 2024 GAAP EPS $(0.17) Beats $(0.38) Estimate, Sales $46.333M Beat $34.763M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) will release its quarterly earnings report on Tuesday, 2024-11-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30.
The announcement from FibroGen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 4.55% increase in the share price the next day.
Here's a look at FibroGen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.26</td>
<td>-0.42</td>
<td>-0.42</td>
<td>-0.68</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.33</td>
<td>-0.57</td>
<td>-0.52</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>18.0%</td>
<td>15.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731337259_0.png" alt="eps graph" />
<h3>Performance of FibroGen Shares</h3>
Shares of FibroGen were trading at $0.323 as of November 08. Over the last 52-week period, shares are down 31.24%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/FGEN/earnings">To track all earnings releases for FibroGen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For FibroGen

Management

FibroGen's CFO Juan Graham, Planned Departure Date Is December 15, 2024

FibroGen Initiated Restructuring Plan Following Negative Pamrevlumab Trial Data; Plan Includes 75% U.S. Workforce Reduction Affecting 127 Employees

FibroGen Raises Full Year Net Product Revenue Guidance To $135M-$150M

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 38.46 percent. This is a 82.22 percent increase over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $50.641 million which beat the analyst consensus estimate of $34.661 million by 46.11 percent. This is a 14.26 percent increase over sales of $44.319 million the same period last year.

FibroGen Q2 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $50.641M Beat $34.661M Estimate

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 400 points on Wednesday.
The Dow traded up 1.07% to 41,177.51 while the NASDAQ rose 3.10% to 17,678.79. The S&amp;P 500 also rose, gaining, 2.08% to 5,549.42.
Leading and Lagging Sectors Information technology shares jumped by 4.3% on Wednesday.
In trading on Wednesday, health care shares rose by just 0.1%.
Top Headline Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported better-than-expected earnings and sales results for its fourth quarter on Tuesday.
Intelligent Cloud segment revenue was $28.5 billion, up 19% year-over-year, while Azure and other cloud services revenue posted year-over-year growth of 29% last quarter.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) shares shot up 40% to $186.83 after the company reported better-than-expected Q3 GAAP EPS and sales.</li>
<li>Shares of Modine Manufacturing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) got a boost, surging 24% to $122.84&nbsp;after the company reported better-than-expected first-quarter financial results.</li>
<li>Fiverr International Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) shares were also up, gaining 22% to $26.78 after the company reported better-than-expected second-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares dropped 61% to $1.31 after the company announced a&nbsp;$10 million&nbsp;registered direct offering of 5 million&nbsp;shares of common stock with unregistered warrants at a price of&nbsp;$2&nbsp;per unit.</li>
<li>Shares of FibroGen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) were down 45% to $0.5640. The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.</li>
<li>PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) was down, falling 35% to $11.05. The company announced clinical data from the first dose cohort of PGN-EDO51.</li>
</ul>
Commodities In commodity news, oil traded up 4.3% to $77.96 while gold traded up 1% at $2,476.40.
Silver traded up 1.5% to $28.945 on Wednesday, while copper rose 2.8% to $4.1965.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.80%, Germany's DAX rose 0.53% and France's CAC 40 gained 0.76%. Spain's IBEX 35 Index fell 1.23%, while London's FTSE 100 rose 1.13%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 gaining 1.49%, Hong Kong's Hang Seng Index jumping 2.01% and S&amp;P BSE Sensex gaining 0.35%.
Economics
<ul>
<li>U.S. pending home sales rose by 4.8% from the prior month in June compared to a revised contraction of 1.9%.</li>
<li>U.S. crude oil inventories declined by 3.436 million barrels in the week ended July 26th, above market estimates of a 1.6 million barrel draw.</li>
<li>Private businesses in the U.S. added 122,000 workers to their payrolls in July, versus a revised 155,000 in June.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">&#8216;</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FVRR

IMNN

MSFT

PEPG

POWL

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday.
The Dow traded up 0.54% to 40,964.19 while the NASDAQ rose 2.53% to 17,581.11. The S&amp;P 500 also rose, gaining, 1.64% to 5,525.69.
Leading and Lagging Sectors Information technology shares rose by 3.5% on Wednesday.
In trading on Wednesday, health care shares fell by 0.1%.
Top Headline The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) shares gained around 4% on Wednesday after the company reported better-than-expected&nbsp;second-quarter&nbsp;adjusted EPS results.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>noco-noco Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares shot up 72% to $0.2638.</li>
<li>Shares of Primech Holdings Ltd &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) got a boost, surging 62% to $0.8531 &nbsp;after gaining over&nbsp;5%&nbsp;on Tuesday.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) shares were also up, gaining 64% to $6.05 after gaining around&nbsp;3%&nbsp;on Tuesday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares dropped 57% to $1.4301 after the company announced a&nbsp;$10 million&nbsp;registered direct offering of 5 million&nbsp; shares of common stock with unregistered warrants at a price of&nbsp;$2&nbsp;per unit.</li>
<li>Shares of FibroGen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) were down 46% to $0.5534. &nbsp;The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.</li>
<li>PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) was down, falling 44% to $9.54. &nbsp;The company announced clinical data from the first dose cohort of PGN-EDO51.</li>
</ul>
Commodities In commodity news, oil traded up 3.8% to $77.56 while gold traded up 0.7% at $2,468.20.
Silver traded up 1.5% to $28.955 on Wednesday, while copper rose 2.5% to $4.1865.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.8%, Germany's DAX rose 0.53% and France's CAC 40 gained 0.76%. Spain's IBEX 35 Index fell 1.23%, while London's FTSE 100 rose 1.13%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 gaining 1.49%, Hong Kong's Hang Seng Index jumping 2.01% and S&amp;P BSE Sensex gaining 0.35%.
Economics
<ul>
<li>U.S. pending home sales rose by 4.8% from the prior month in June compared to a revised contraction of 1.9%.</li>
<li>U.S. crude oil inventories declined by 3.436 million barrels in the week ended July 26th, above market estimates of a 1.6 million barrel draw.</li>
<li>Private businesses in the U.S. added 122,000 workers to their payrolls in July, versus a revised 155,000 in June.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">&#8216;</a></li>
</ul>

NCNC

NUZE

PMEC

Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings

FibroGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in <a href="https://www.benzinga.com/pressreleases/24/07/g40049878/fibrogen-announces-topline-results-from-two-late-stage-pamrevlumab-pancreatic-cancer-studies-and-p" target="_blank" rel="noreferrer noopener">pancreatic cancer patients</a>.
What Happened: The pamrevlumab arm of the study did not meet the primary endpoint of overall survival.
Based upon the results of the late-stage pamrevlumab trials in pancreatic cancer, the company plans to implement an immediate and significant cost reduction plan in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38070160/fibrogen-unveils-early-data-from-prostate-cancer-candidate-analyst-advocates-furthe" rel="noreferrer noopener">FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape</a>.
And the pamrevlumab development program will be terminated. 
As a result of the cost reduction plan, headcount in the U.S. will be reduced by approximately 75%.
Median overall survival of 17.3 months was observed in the pamrevlumab combined with gemcitabine + nab-paclitaxel or FOLFIRINOX arm compared to the median overall survival of 17.9 months in the control arm of placebo combined with gemcitabine + nab-paclitaxel or FOLFIRINOX (HR: 1.08)
The preliminary safety analyses across both studies indicate that the safety profile of pamrevlumab combined with gemcitabine + nab-paclitaxel or FOLFIRINOX was generally well tolerated, with an acceptable safety profile.
No clinically meaningful differences in treatment-emergent adverse events were seen between the treatment arms.
William Blair writes, &#8220;We believe investors had exceedingly low expectations for pamrevlumab in pancreatic cancer following several clinical setbacks in both idiopathic pulmonary fibrosis and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/34109907/three-in-a-row-fibrogens-investigational-drug-flunks-in-another-study-for-rare-dise" target="_blank" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.&#8221;
The analyst notes that investor interest in FibroGen has surged following recent mergers and acquisitions in the antibody-drug conjugates (ADC) sector and the release of competitive topline data.
The primary focus is on FG-3246, an ADC targeting CD46. The company plans to start a Phase 2/3 monotherapy trial later this year, with the Phase 3 portion potentially beginning in the first half of 2027. Notably, FG-3246 is the only clinical pipeline candidate with a possible registrational-enabling study in the near future.
William Blair reiterates <a target="_blank" href="https://www.benzinga.com/quote/FGEN/analyst-ratings" rel="noreferrer noopener">the Market Perform rating</a>.
Price Action: FGEN stock is down 47.9% at 54 cents at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40070046/insurance-giant-humana-stock-tumbles-after-q2-earnings-beat-issues-sub-par-profit-outlook" target="_blank" rel="noreferrer noopener">Insurance Giant Humana Stock Tumbles After Q2 Earnings Beat, Issues Sub Par Profit Outlook</a>.</li>
</ul>

Analyst Color

Health Care

Reiteration

Analyst Ratings

General

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen shares are trading lower. The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.

Shares of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares rose sharply in today's pre-market trading following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/40060832/amd-skyrockets-over-9-lifting-along-with-ai-rival-nvidia-whats-going-on">second-quarter earnings</a>.
AMD reported quarterly earnings of 69 cents per share which beat the analyst consensus estimate of 68 cents per share. The company reported quarterly sales of $5.835 billion which beat the analyst consensus estimate of $5.724 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AMD shares jumped 9.1% to $151.01 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Primech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) gained 114.8% to $1.13 in pre-market trading after gaining over 5% on Tuesday.</li>
<li>Heramba Electric plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares climbed 92.8% to $8.29 in pre-market trading after dipping around 49% on Tuesday.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) rose 79.4% to $6.64 in pre-market trading after gaining around 3% on Tuesday.</li>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) gained 39.8% to $5.52 in pre-market trading.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares gained 33.1% to $0.4205 in pre-market trading after the company regained Nasdaq compliance.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) gained 25.3% to $167.02 in pre-market trading after posting better-than-expected third-quarter results.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares gained 22.8% to $0.48 in pre-market trading after dipping 66% on Tuesday.      </li>
<li>DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) shares gained 19.1% to $3.91 in pre-market trading after the company reported a year-over-year increase in second-quarter financial results.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) gained 12.1% to $77.35 in pre-market trading after the company announced that the Nuclear Regulatory Commission has approved its request to extend the operation of Comanche Peak Nuclear Power Plant through 2053.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>FibroGen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares fell 40.2% to $0.6159 in pre-market trading. The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.</li>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares declined 24% to $3.99 in pre-market trading. The company announced a presentation of clinical data from the TAMARACK Phase 2 study of vobramitamab duocarmazine at the upcoming European Society for Medical Oncology Congress 2024.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) fell 21.5% to $0.2631 in pre-market trading. Jet.AI announced expiration and successful results of exchange offer and consent solicitation relating to warrants.</li>
<li>Velo3D, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) shares fell 20.6% to $2.20 in pre-market trading after declining 4% on Tuesday.</li>
<li>Penumbra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) shares fell 20.3% to $137.93 in pre-market trading after the company reported second-quarter financial results and cut its FY24 revenue guidance below estimates.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares declined 18.6% to $12.75 in pre-market trading following a second-quarter EPS miss.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) shares fell 17.6% to $4.71 in pre-market trading. Needham analyst Ryan MacDonald reiterated Definitive Healthcare with a Hold.</li>
<li>O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) fell 15.5% to $9.80 in pre-market trading after the company lowered its FY24 guidance.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares dipped 14.6% to $19.33 in pre-market trading following quarterly results.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares fell 12.4% to $0.5056 in pre-market trading after dipping 18% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40059087/nasdaq-tumbles-amid-decline-in-tech-stocks-greed-index-moves-to-fear-zone">Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

BIMI

DALN

FFIE

JTAI

LMND

MGNX

PITA

TBIO

TIVC

Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

<ul>
<li>Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis</li>
<li>LAPIS study in locally advanced, unresectable pancreatic cancer, sponsored by FibroGen, did not meet the primary endpoint of overall survival</li>
<li>Pamrevlumab was generally safe and well tolerated across both studies, with no clinically meaningful difference in overall safety vs. control arms &nbsp;</li>
<li>Company to implement immediate and significant cost reduction plan in the U.S. 
<ul>
<li>Terminate pamrevlumab research and development (R&amp;D) investment and expeditiously wind down remaining obligations</li>
<li>Reduce U.S. workforce by approximately 75%</li>
</ul>
</li>
</ul>

FibroGen Announces Topline Results From Two Late-Stage Pamrevlumab Pancreatic Cancer Studies; Pamrevlumab Arm Of Precision PromiseSM Study In Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint

Trading Halt: Halted at 4:00:59 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. The company's market cap stands at $1.5 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock rose 33.56% to $0.31. The market value of their outstanding shares is at $6.1 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares increased by 21.43% to $0.78. The market value of their outstanding shares is at $14.6 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock rose 11.68% to $1.29. The company's market cap stands at $189.2 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 10.74% to $0.71. The company's market cap stands at $52.3 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares rose 10.54% to $0.76. The market value of their outstanding shares is at $75.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock declined by 7.0% to $0.21 during Thursday's regular session. The company's market cap stands at $4.9 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock declined by 6.17% to $1.37. The company's market cap stands at $1.1 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares decreased by 5.78% to $0.72. The market value of their outstanding shares is at $2.7 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock fell 5.33% to $0.89. The market value of their outstanding shares is at $5.7 million. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) shares fell 5.2% to $3.02. The company's market cap stands at $5.9 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock decreased by 5.11% to $2.23. The market value of their outstanding shares is at $8.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIMD

AMIX

CMAX

CNSP

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RSLS

STSS

TENX

TNON

12 Health Care Stocks Moving In Thursday's Intraday Session

FibroGen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new <a href="https://www.benzinga.com/pressreleases/24/06/g39145782/fibrogen-announces-clinical-trial-supply-agreement-with-regeneron-pharmaceuticals-to-evaluate-fibr" target="_blank" rel="noreferrer noopener">clinical trial supply agreement with Regeneron</a>.
The Details: FibroGen announced that the&nbsp;<a href="https://www.benzinga.com/pressreleases/24/06/g39145655/fibrogen-announces-fda-clearance-of-investigational-new-drug-application-for-fg-3165-a-galectin-9-" target="_blank" rel="noreferrer noopener">FDA cleared its IND of FG-3165</a>, allowing the company to initiate a Phase 1 clinical trial.
FG-3165 is a galectin-9 targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. Phase 1 trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors are expected to begin enrollment in the second half of 2024.&nbsp;
"To date, FG-3165 has demonstrated anti-tumor activity with improved survival in combination with other immune modulatory therapies in mouse cancer models and has shown excellent tolerability in nonclinical safety studies," said&nbsp;Thane Wettig, CEO of FibroGen.
FibroGen also announced&nbsp;a clinical trial supply agreement with Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) to evaluate FibroGen's immuno-oncology assets FG-3165 and FG-3175 with Reneneron's anti-PD-1 therapy LIBTAYO&nbsp;(cemiplimab) in patients with solid tumors.
FibroGen will be the sponsor of each Phase 1 monotherapy and combination trial. Regeneron will provide drug supply to FibroGen. Each company will retain all rights to their respective compounds.
"We believe that the mechanisms of action for both FG-3165 (anti-Gal9) and FG-3175 (anti-CCR8) have the potential to be synergistic with cemiplimab, providing the possibility for an improvement in clinical outcomes for patients. We look forward to building a collaborative relationship with Regeneron," said&nbsp;Deyaa Adib, chief medical officer of FibroGen.
Don&#8217;t Miss: <a href="https://www.benzinga.com/markets/equities/24/06/39156451/why-microalgo-wimi-hologram-cloud-shares-are-jumping-premarket-today">Why MicroAlgo &amp; WiMi Hologram Cloud Shares Are Jumping Premarket Today</a>
FGEN Price Action: FibroGen shares were up around 14% in early trading before pulling back. The stock was down 1.63% at $1.21 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With FibroGen Stock Tuesday?

In a report released today, Paul Choi from Goldman Sachs maintained a Sell rating on FibroGen (FGEN – Research Report), with a price target of $0.6...

FibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside Potential

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

FibroGen CFO, CMO to leave company by year's end

The latest update is out from FibroGen ( ($FGEN) ). FibroGen, Inc. is streamlining its U.S. operations with a significant cost reduction strategy, ...

FibroGen Executives Depart Amid U.S. Operations Overhaul

FibroGen ( ($FGEN) ) has shared an announcement. Suzanne Blaug, Benjamin Cravatt, and Gerald Lema have resigned from the Board of Directors of Fibr...

FibroGen Announces Board Member Resignations and Committee Appointments

FibroGen ( ($FGEN) ) has issued an update. FibroGen, Inc. has taken a strategic step to cut costs and safeguard its finances by terminating its lea...

FibroGen Cuts Costs by Terminating San Francisco Lease Early

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Disc Medicine (IRON) announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Kaushik most recently served...

Disc Medicine appoints Kaushik as Chief Technical Officer

FibroGen GAAP EPS of -$0.17 beats by $0.06, revenue of $46.3M beats by $11.54M

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

ABUS

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

GLYC

HLVX

IBRX

INAB

IRON

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

Comments

FibroGen

매도 수량

FibroGen (NASDAQ:FGEN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌